SAM
TVTX icon

Shell Asset Management’s Travere Therapeutics TVTX Stock Holding History

Shell Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$51K Sell
2,142
-3,256
-60% -$61.2K 0.01% 862
2025
Q2 		$80K Sell
5,398
-580
-10% -$9.61K ﹤0.01% 1052
2025
Q1 		$107K Sell
5,978
-69
-1% -$1.4K 0.01% 998
2024
Q4 		$105K Sell
6,047
-301
-5% -$5.32K ﹤0.01% 1042
2024
Q3 		$89K Buy
+6,348
New +$66.1K ﹤0.01% 1072
2024
Q1 		$55K Sell
6,704
-452
-6% -$3.81K ﹤0.01% 1145
2023
Q4 		$64K Sell
7,156
-2,151
-23% -$15.7K ﹤0.01% 1138
2023
Q3 		$83K Sell
9,307
-147
-2% -$2.07K ﹤0.01% 1120
2023
Q2 		$145K Sell
9,454
-54
-0.6% -$982 0.01% 1024
2023
Q1 		$214K Sell
9,508
-33
-0.3% -$701 0.01% 905
2022
Q4 		$201K Sell
9,541
-1,936
-17% -$41K 0.01% 946
2022
Q3 		$283K Sell
11,477
-3,008
-21% -$77.7K 0.01% 855
2022
Q2 		$351K Buy
14,485
+24
+0.2% +$604 0.01% 901
2022
Q1 		$373K Sell
14,461
-2,140
-13% -$56.8K 0.01% 952
2021
Q4 		$515K Buy
16,601
+74
+0.4% +$2.08K 0.01% 887
2021
Q3 		$401K Sell
16,527
-710
-4% -$13K 0.01% 965
2021
Q2 		$251K Buy
17,237
+930
+6% +$18.3K ﹤0.01% 1174
2021
Q1 		$407K Buy
16,307
+9,426
+137% +$260K 0.01% 936
2020
Q4 		$188K Hold
6,881
– – ﹤0.01% 1131
2020
Q3 		$127K Hold
6,881
– – ﹤0.01% 1135
2020
Q2 		$140K Sell
6,881
-71
-1% -$1.13K ﹤0.01% 1100
2020
Q1 		$101K Sell
6,952
-105
-1% -$1.58K ﹤0.01% 1118
2019
Q4 		$100K Sell
7,057
-149
-2% -$1.9K ﹤0.01% 1184
2019
Q3 		$84K Sell
7,206
-62
-0.9% -$1.02K ﹤0.01% 1202
2019
Q2 		$146K Sell
7,268
-165
-2% -$3.26K ﹤0.01% 1147
2019
Q1 		$168K Hold
7,433
– – ﹤0.01% 1124
2018
Q4 		$168K Sell
7,433
-600
-7% -$14.9K ﹤0.01% 1059
2018
Q3 		$231K Buy
+8,033
New +$230K ﹤0.01% 1093

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Shell Asset Management's TVTX Position: Q3 2025 in Review

Shell Asset Management reduced its Travere Therapeutics (TVTX) stake by 60% in Q3 2025, selling an estimated $61.2K and leaving 2,142 shares worth $51K. The position accounts for 0.01% of the portfolio, ranked #862.

Shell Asset Management first reported a position in TVTX in Q3 2018 and has held it in 28 quarters since. The position peaked at $515K in Q4 2021. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Shell Asset Management held 2,142 shares of Travere Therapeutics worth $51K as of Q3 2025.
  • Shell Asset Management sold 3,256 Travere Therapeutics shares in Q3 2025, an estimated $61.2K.
  • Travere Therapeutics made up 0.01% of Shell Asset Management's portfolio in Q3 2025, its #862 holding.
  • Shell Asset Management first reported a position in Travere Therapeutics in Q3 2018 and has held it in 28 quarters since.
  • Shell Asset Management's Travere Therapeutics position peaked at $515K in Q4 2021.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.